Literature DB >> 8216353

Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension.

S S Arcot1, D W Lipke, M N Gillespie, J W Olson.   

Abstract

Although pathologic and hemodynamic changes in monocrotaline (MCT)-induced pulmonary hypertension have been studied extensively, relatively little is known about the inter- and intracellular signaling mechanisms underlying such alterations. As a first step to delineating signaling mechanisms governing adverse structural alterations in the hypertensive lungs, we examined changes in the steady-state levels of mRNAs encoding several growth factors including transforming growth factors (TGF), platelet-derived growth factors (PDGF), vascular endothelial cell growth factor (VEGF) and endothelin (ET) as a function of time in MCT-induced pulmonary hypertension in rats. These studies demonstrated a very diverse pattern of growth factor gene expression in response to MCT administration. In general, alterations in the steady-state levels of mRNAs encoding the growth factors preceded the onset of MCT-induced pulmonary hypertension. TGF-beta 1, -beta 2 and -beta 3 transcripts were seen to be elevated, whereas that of TGF-alpha and PDGF-A remained unchanged. Transcripts for PDGF-B and ET were increased in the early stages but declined to less than controls in the latter stages of MCT-induced hypertension. In contrast, levels of VEGF mRNA decreased to less than controls as the disease progressed. Viewed collectively, the diverse pattern of expression suggests that alterations in the levels of the growth factor transcripts may have a significant role in the development of pulmonary hypertensive disease and may be relevant to the pathological and structural changes in MCT-induced pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216353     DOI: 10.1016/0006-2952(93)90675-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats.

Authors:  Aikaterini J Megalou; Chryssoula Glava; Dimitrios L Oikonomidis; Agapi Vilaeti; Maria G Agelaki; Giannis G Baltogiannis; Apostolos Papalois; Antonios P Vlahos; Theofilos M Kolettis
Journal:  Int J Clin Exp Med       Date:  2010-10-23

2.  Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease.

Authors:  Wanli Ma; Weihong Han; Peter A Greer; Rubin M Tuder; Haroldo A Toque; Kevin K W Wang; R William Caldwell; Yunchao Su
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

3.  EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Authors:  Ankang Lu; Caojian Zuo; Yuhu He; Guilin Chen; Lingjuan Piao; Jian Zhang; Bing Xiao; Yujun Shen; Juan Tang; Deping Kong; Sara Alberti; Di Chen; Shenkai Zuo; Qianqian Zhang; Shuai Yan; Xiaochun Fei; Fei Yuan; Bin Zhou; Shengzhong Duan; Yu Yu; Michael Lazarus; Yunchao Su; Richard M Breyer; Colin D Funk; Ying Yu
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

4.  Monocrotaline-induced pulmonary hypertension with sufficient tricuspid regurgitation in a rat model.

Authors:  Fuminobu Ishikura; Ryoko Azakami; Toshihiko Asanuma; Shintaro Beppu
Journal:  J Med Ultrason (2001)       Date:  2012-05-24       Impact factor: 1.314

5.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Authors:  Brian B Graham; Margaret M Mentink-Kane; Hazim El-Haddad; Shawn Purnell; Li Zhang; Ari Zaiman; Elizabeth F Redente; David W H Riches; Paul M Hassoun; Angela Bandeira; Hunter C Champion; Ghazwan Butrous; Thomas A Wynn; Rubin M Tuder
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

Review 6.  Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective.

Authors:  Brian B Graham; Angela Pontes Bandeira; Nicholas W Morrell; Ghazwan Butrous; Rubin M Tuder
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

7.  Role of miR206 in genistein-induced rescue of pulmonary hypertension in monocrotaline model.

Authors:  Salil Sharma; Soban Umar; Alexander Centala; Mansoureh Eghbali
Journal:  J Appl Physiol (1985)       Date:  2015-10-15

8.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Authors:  M Sean McMurtry; Stephen L Archer; Dario C Altieri; Sebastien Bonnet; Alois Haromy; Gwyneth Harry; Sandra Bonnet; Lakshmi Puttagunta; Evangelos D Michelakis
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 9.  Vascular repair and regeneration as a therapeutic target for pulmonary arterial hypertension.

Authors:  Laszlo Farkas; Martin Kolb
Journal:  Respiration       Date:  2013-03-22       Impact factor: 3.580

10.  Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells.

Authors:  Prasanna Abeyrathna; Laszlo Kovacs; Weihong Han; Yunchao Su
Journal:  Am J Physiol Cell Physiol       Date:  2016-04-20       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.